RxDoctor Payments Data

Ranu Choudhary, MD

Internal Medicine · Kent, WANPI 1386664183

Payments from drug & device makers

$434in general payments, 2019–2025

Across 31 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$212
  • Novo Nordisk$63
  • GSK$50
  • Takeda Pharmaceuticals U.S.A., Inc.$30
  • Amgen$27
  • Astellas Pharma US Inc$17
  • plus $35 from 3 others

What the payments were for

  • Food & beverage$42097%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$434 in reported general payments places this provider in the 80th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$108,483
Medicare patients
212
Services billed
1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$126,539
TrulicityDulaglutide76$114,296
FarxigaDapagliflozin Propanediol90$103,316
EliquisApixaban72$92,658
JardianceEmpagliflozin54$69,428
MounjaroTirzepatide42$62,499
XareltoRivaroxaban50$56,989
CreonLipase/Protease/Amylase17$47,517
Tresiba Flextouch U-100Insulin Degludec56$40,622
MyrbetriqMirabegron54$40,195
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$26,061
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$24,921
Tresiba Flextouch U-200Insulin Degludec13$20,154
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$18,401
JanuviaSitagliptin Phosphate11$15,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$16$130,370137 claims
Novo NordiskOzempic$63$126,53999 claims
AbbVieCreon, Synthroid$212$52,44270 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta$50$44,69568 claims
Astellas Pharma US IncMyrbetriq$17$40,19554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Kent

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →